Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
38.50
-0.41 (-1.05%)
Dec 5, 2025, 4:00 PM EST - Market closed

Mineralys Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-171.36-177.81-71.9-29.8-19.41-3.43
Depreciation & Amortization
0.060.04----
Loss (Gain) From Sale of Investments
-7.01-9.41-6.87-0.65--
Stock-Based Compensation
17.1711.345.060.460.080
Other Operating Activities
----0.680.48
Change in Accounts Payable
-8.124.162.423.014.470.54
Change in Other Net Operating Assets
-2.125.36-9.89-2.24-0.39-0.06
Operating Cash Flow
-171.37-166.31-81.17-29.22-14.56-2.46
Capital Expenditures
--0.1----
Investment in Securities
-202.69115.06-160.47-21.76--
Investing Cash Flow
-202.69114.96-160.47-21.76--
Short-Term Debt Issued
-----3.85
Total Debt Issued
-----3.85
Net Debt Issued (Repaid)
-----3.85
Issuance of Common Stock
494.52116.58203.25---
Other Financing Activities
-0.13-0.44--1.63--0.02
Financing Cash Flow
494.39116.14203.25128.0223.813.83
Net Cash Flow
120.3264.79-38.477.049.251.37
Free Cash Flow
-171.37-166.41-81.17-29.22-14.56-2.46
Free Cash Flow Per Share
-2.86-3.43-2.24-5.66-2.92-0.53
Levered Free Cash Flow
-107.66-99.43-55.27-18.4-7.62-
Unlevered Free Cash Flow
-107.66-99.43-55.27-18.4-7.61-
Change in Working Capital
-10.239.52-7.470.774.090.48
Source: S&P Capital IQ. Standard template. Financial Sources.